Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Evaxion stock jumps on expanded vaccine development pact with MSD
Evaxion Biotech (EVAX) shares gained roughly 17% in early trade on Thursday after the company announced an expansion of its vaccine development collaboration with MSD (NYSE:MRK) (tradename of Merck & Co.
Evaxion Biotech Partners With Merck To Expand Vaccine Development
Evaxion Biotech A/S (NASDAQ:EVAX) inked an option and licensing deal with Merck & Co., Inc (NYSE:MRK) for two preclinical vaccine candidates. Evaxion also granted Merck an option to license preclinical vaccine candidates EVX-B2 and EVX-B3.
Evaxion significantly expands vaccine deal with MSD
Danish clinical-stage AI-based vaccine developer Evaxion Biotech (Nasdaq: EVAX) has entered into an option and license agreement with MSD (tradename of Merck & Co [NYSE: MRK] outside of the USA and Canada),
Evaxion Biotech Gains Buy Rating Amid Merck Collaboration and AI-Driven Vaccine Development Prospects
Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Evaxion Biotech (EVAX – Research Report). The
FierceBiotech
5d
Merck bags options on Evaxion's AI-designed vaccines, offering small upfront and big back end
Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...
5d
Evaxion significantly expands vaccine development collaboration with MSD
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a ...
Yahoo Finance
12d
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
19, 2024 (GLOBE NEWSWIRE) --
Evaxion
Biotech A/S (NASDAQ: EVAX) (“
Evaxion
”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, launches an enhanced ...
5d
Evaxion Biotech与MSD达成疫苗许可协议
根据协议条款,Evaxion授予MSD独家许可其疫苗候选物EVX-B2和EVX-B3的选择权。EVX-B2旨在预防淋病,而EVX-B3则针对一种未披露的传染因子。Evaxion将获得320万美元的预付款,如果MSD在2025年行使其许可选择权,Evaxion可能获得高达1000万美元。此外,Evaxion每种产品可能获得高达5.92亿美元的里程碑付款,外加净销售额的特许权使用费。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback